approved

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Walking the Tightrope

As we stand on the verge of a new era in crypto, it’s crucial to reaffirm the importance of decentralization. Beyond being a mere aspiration, decentralization serves as the lifeblood of the crypto world, standing as the pivotal force that draws the line between freedom and control. Amidst the hype surrounding the impending approval of a spot Bitcoin ETF in the United States, accompanied by the influx of capital from behemoths like BlackRock, the immediate market surge raises a serious question for the future of crypto. Are people here for

Clockout Breaks New Ground in Wage Access. Launches and Expands its Reach to 42 States

Historically, on-demand wage access required significant backend adjustments, coordination and often posed integration hurdles for employers. Clockout, a cutting-edge fintech platform, is pushing the boundaries of the traditional earned wage access model. In a bold move to address common industry challenges, the company has unveiled a streamlined, implementation-free model for employers, eliminating the need for cumbersome contracts and implementations and making offering their workforce immediate access to earned wages effortless. Clockout amplifies businesses' employee motivation, retention, and hiring leverage; while placing the power directly in the hands of the employees

UNBINARY, the VR hand-painted puzzle adventure, was approved by Quest Store and started the QA process. It will be ready in Early 2022.

Celebrating this milestone, Ludact unveiled a story trailer of UNBINARY and made major updates on Early Access with requested features and new levels. Today, the Brazilian indie game studio Ludact announced the official approval for release UNBINARY on the Quest Store and a simultaneous launch for Meta Quest and PC VR in Early 2022. Included is the release of "Meet Webby", a story trailer showing more about the mind of the sarcastic AI and the hand-painted comic book art style. A major update was made today on the Early Access